Literature DB >> 20596031

The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration.

O Abdel-Wahab, O Kilpivaara, J Patel, L Busque, R L Levine.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20596031      PMCID： PMC4654627          DOI： 10.1038/leu.2010.144

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  8 in total

1.  Mutations of ASXL1 gene in myeloproliferative neoplasms.

Authors:  N Carbuccia; A Murati; V Trouplin; M Brecqueville; J Adélaïde; J Rey; W Vainchenker; O A Bernard; M Chaffanet; N Vey; D Birnbaum; M J Mozziconacci
Journal:  Leukemia       Date:  2009-07-16       Impact factor: 11.528

2.  Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias.

Authors:  N Carbuccia; V Trouplin; V Gelsi-Boyer; A Murati; J Rocquain; J Adélaïde; S Olschwang; L Xerri; N Vey; M Chaffanet; D Birnbaum; M J Mozziconacci
Journal:  Leukemia       Date:  2009-10-29       Impact factor: 11.528

3.  Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia.

Authors:  J Boultwood; J Perry; A Pellagatti; M Fernandez-Mercado; C Fernandez-Santamaria; M J Calasanz; M J Larrayoz; M Garcia-Delgado; A Giagounidis; L Malcovati; M G Della Porta; M Jädersten; S Killick; E Hellström-Lindberg; M Cazzola; J S Wainscoat
Journal:  Leukemia       Date:  2010-02-25       Impact factor: 11.528

4.  PCR amplification introduces errors into mononucleotide and dinucleotide repeat sequences.

Authors:  L A Clarke; C S Rebelo; J Gonçalves; M G Boavida; P Jordan
Journal:  Mol Pathol       Date:  2001-10

5.  Improving sequencing quality from PCR products containing long mononucleotide repeats.

Authors:  Aron Fazekas; Royce Steeves; Steven Newmaster
Journal:  Biotechniques       Date:  2010-04       Impact factor: 1.993

6.  High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression.

Authors:  J Boultwood; J Perry; R Zaman; C Fernandez-Santamaria; T Littlewood; R Kusec; A Pellagatti; L Wang; R E Clark; J S Wainscoat
Journal:  Leukemia       Date:  2010-04-22       Impact factor: 11.528

7.  Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia.

Authors:  Véronique Gelsi-Boyer; Virginie Trouplin; José Adélaïde; Julien Bonansea; Nathalie Cervera; Nadine Carbuccia; Arnaud Lagarde; Thomas Prebet; Meyer Nezri; Danielle Sainty; Sylviane Olschwang; Luc Xerri; Max Chaffanet; Marie-Joëlle Mozziconacci; Norbert Vey; Daniel Birnbaum
Journal:  Br J Haematol       Date:  2009-04-15       Impact factor: 6.998

8.  Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.

Authors:  Omar Abdel-Wahab; Taghi Manshouri; Jay Patel; Kelly Harris; Jinjuan Yao; Cyrus Hedvat; Adriana Heguy; Carlos Bueso-Ramos; Hagop Kantarjian; Ross L Levine; Srdan Verstovsek
Journal:  Cancer Res       Date:  2010-01-12       Impact factor: 12.701
  8 in total
  27 in total

Review 1.  Disordered epigenetic regulation in the pathophysiology of myeloproliferative neoplasms.

Authors:  Su-Jiang Zhang; Omar Abdel-Wahab
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

2.  CBL mutations in myeloproliferative neoplasms are also found in the gene's proline-rich domain and in patients with the V617FJAK2.

Authors:  Paula Aranaz; Cristina Hurtado; Ignacio Erquiaga; Itziar Miguéliz; Cristina Ormazábal; Ion Cristobal; Marina García-Delgado; Francisco Javier Novo; José Luis Vizmanos
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

3.  Discriminating a common somatic ASXL1 mutation (c.1934dup; p.G646Wfs*12) from artifact in myeloid malignancies using NGS.

Authors:  Michael O Alberti; Sridhar Nonavinkere Srivatsan; Jin Shao; Samantha N McNulty; Gue Su Chang; Christopher A Miller; Jennifer B Dunlap; Fei Yang; Richard D Press; Qingsong Gao; Li Ding; Jonathan W Heusel; Eric J Duncavage; Matthew J Walter
Journal:  Leukemia       Date:  2018-06-29       Impact factor: 11.528

4.  Somatic mutations in murine models of leukemia and lymphoma: Disease specificity and clinical relevance.

Authors:  Liat Goldberg; Sheryl M Gough; Fan Lee; Christine Dang; Robert L Walker; Yuelin J Zhu; Sven Bilke; Marbin Pineda; Masahiro Onozawa; Yang Jo Chung; Paul S Meltzer; Peter D Aplan
Journal:  Genes Chromosomes Cancer       Date:  2017-03-31       Impact factor: 5.006

5.  Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value.

Authors:  Marta Pratcorona; Saman Abbas; Mathijs A Sanders; Jasper E Koenders; François G Kavelaars; Claudia A J Erpelinck-Verschueren; Annelieke Zeilemakers; Bob Löwenberg; Peter J M Valk
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

6.  ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.

Authors:  Klaus H Metzeler; Heiko Becker; Kati Maharry; Michael D Radmacher; Jessica Kohlschmidt; Krzysztof Mrózek; Deedra Nicolet; Susan P Whitman; Yue-Zhong Wu; Sebastian Schwind; Bayard L Powell; Thomas H Carter; Meir Wetzler; Joseph O Moore; Jonathan E Kolitz; Maria R Baer; Andrew J Carroll; Richard A Larson; Michael A Caligiuri; Guido Marcucci; Clara D Bloomfield
Journal:  Blood       Date:  2011-10-26       Impact factor: 22.113

7.  Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?

Authors:  Guillermo F Sanz; Mariam Ibañez; Esperanza Such
Journal:  Blood Adv       Date:  2019-11-12

8.  Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.

Authors:  Anna M Jankowska; Hideki Makishima; Ramon V Tiu; Hadrian Szpurka; Yun Huang; Fabiola Traina; Valeria Visconte; Yuka Sugimoto; Courtney Prince; Christine O'Keefe; Eric D Hsi; Alan List; Mikkael A Sekeres; Anjana Rao; Michael A McDevitt; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

9.  Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.

Authors:  Brady L Stein; Donna M Williams; Christine O'Keefe; Ophelia Rogers; Roxann G Ingersoll; Jerry L Spivak; Amit Verma; Jarek P Maciejewski; Michael A McDevitt; Alison R Moliterno
Journal:  Haematologica       Date:  2011-06-28       Impact factor: 9.941

10.  Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations.

Authors:  Daichi Inoue; Jiro Kitaura; Katsuhiro Togami; Koutarou Nishimura; Yutaka Enomoto; Tomoyuki Uchida; Yuki Kagiyama; Kimihito Cojin Kawabata; Fumio Nakahara; Kumi Izawa; Toshihiko Oki; Akie Maehara; Masamichi Isobe; Akiho Tsuchiya; Yuka Harada; Hironori Harada; Takahiro Ochiya; Hiroyuki Aburatani; Hiroshi Kimura; Felicitas Thol; Michael Heuser; Ross L Levine; Omar Abdel-Wahab; Toshio Kitamura
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.